RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aveo Pharmaceuticals Stock

Aveo Pharmaceuticals Net Income 2024

Aveo Pharmaceuticals Net Income

45.86 M USD

Ticker

AVEO

ISIN

US0535883070

WKN

A2P0CL

In 2024, Aveo Pharmaceuticals's profit amounted to 45.86 M USD, a 140.99% increase from the 19.03 M USD profit recorded in the previous year.

The Aveo Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2026e115.32
2025e72
2024e45.86
2023e19.03
2022e-23.99
2021-53.34
2020-35.6
20199.4
2018-5.3
2017-65
2016-26.9
2015-15
2014-52.7
2013-107
2012-114.4
201130.6
2010-58.8
2009-44.1
2008-32.5
2007-25
2006-24.9
2005-16.1

Aveo Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aveo Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aveo Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aveo Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aveo Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aveo Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aveo Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aveo Pharmaceuticals’s growth potential.

Aveo Pharmaceuticals Revenue, EBIT and net profit per share

DateAveo Pharmaceuticals RevenueAveo Pharmaceuticals EBITAveo Pharmaceuticals Net Income
2026e355.73 M USD211.53 M USD115.32 M USD
2025e305.22 M USD109.61 M USD72 M USD
2024e233.91 M USD58.33 M USD45.86 M USD
2023e184.75 M USD26.61 M USD19.03 M USD
2022e114.29 M USD-19.18 M USD-23.99 M USD
202142.3 M USD-49.55 M USD-53.34 M USD
20206 M USD-38.9 M USD-35.6 M USD
201928.8 M USD-400,000 USD9.4 M USD
20185.4 M USD-26.1 M USD-5.3 M USD
20177.6 M USD-26.7 M USD-65 M USD
20162.5 M USD-29.4 M USD-26.9 M USD
201519 M USD-8.1 M USD-15 M USD
201418.1 M USD-38.7 M USD-52.7 M USD
20131.3 M USD-95.9 M USD-107 M USD
201219.3 M USD-109 M USD-114.4 M USD
2011164.8 M USD33.9 M USD30.6 M USD
201044.7 M USD-56.4 M USD-58.8 M USD
200920.7 M USD-41.2 M USD-44.1 M USD
200819.7 M USD-31.4 M USD-32.5 M USD
200711 M USD-24.7 M USD-25 M USD
20067.8 M USD-24.2 M USD-24.9 M USD
20056.2 M USD-16.3 M USD-16.1 M USD

Aveo Pharmaceuticals stock margins

The Aveo Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aveo Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aveo Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aveo Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aveo Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aveo Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aveo Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aveo Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aveo Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aveo Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aveo Pharmaceuticals Margin History

Aveo Pharmaceuticals Gross marginAveo Pharmaceuticals Profit marginAveo Pharmaceuticals EBIT marginAveo Pharmaceuticals Profit margin
2026e88.8 %59.46 %32.42 %
2025e88.8 %35.91 %23.59 %
2024e88.8 %24.94 %19.61 %
2023e88.8 %14.4 %10.3 %
2022e88.8 %-16.78 %-20.99 %
202188.8 %-117.16 %-126.12 %
202088.8 %-648.33 %-593.33 %
201988.8 %-1.39 %32.64 %
201888.8 %-483.33 %-98.15 %
201788.8 %-351.32 %-855.26 %
201688.8 %-1,176 %-1,076 %
201588.8 %-42.63 %-78.95 %
201488.8 %-213.81 %-291.16 %
201388.8 %-7,376.92 %-8,230.77 %
201288.8 %-564.77 %-592.75 %
201188.8 %20.57 %18.57 %
201088.8 %-126.17 %-131.54 %
200988.8 %-199.03 %-213.04 %
200888.8 %-159.39 %-164.97 %
200788.8 %-224.55 %-227.27 %
200688.8 %-310.26 %-319.23 %
200588.8 %-262.9 %-259.68 %

Aveo Pharmaceuticals Aktienanalyse

What does Aveo Pharmaceuticals do?

Aveo Pharmaceuticals Inc. is a bio-pharmaceutical company focused on the development of new therapies for cancer patients. The company was founded in 2001 in Cambridge, Massachusetts and is listed on the NASDAQ stock exchange under the ticker symbol AVEO. The history of Aveo Pharmaceuticals began with the discovery of a growth factor responsible for the formation of blood vessels in tumors. In collaboration with Harvard Medical School and the Dana-Farber Cancer Institute, the company developed a new drug called Tivozanib, which can block this growth factor. Tivozanib has been tested as a potential treatment for various types of cancer, including kidney cancer, breast cancer, and lung cancer, and is currently in various stages of development. Aveo Pharmaceuticals employs a collaborative business model to involve scientists and researchers in the development of new therapies. The company works together with leading academic institutions and bio-pharmaceutical companies to accelerate and improve the drug development process. Aveo Pharmaceuticals is divided into different divisions that focus on the development of therapies for different types of cancer. These divisions include oncology, which focuses on the development of therapies for solid tumors, as well as hematology, which focuses on the development of therapies for blood cancer. Aveo Pharmaceuticals also has a pipeline of products in various stages of development. These products include both novel drugs and therapies that are already on the market. One of Aveo Pharmaceuticals' most promising products is the drug Tivozanib. Tivozanib is a kinase inhibitor specifically designed for the treatment of kidney cancer. The drug has proven to be effective in clinical trials and could soon be approved by the U.S. Food and Drug Administration (FDA). Tivozanib could improve both the quality of life and the survival rate of kidney cancer patients. Another promising drug from Aveo Pharmaceuticals is Ficlatuzumab, a drug specifically designed for the treatment of solid tumors. Ficlatuzumab targets the hepatocyte growth factor receptor (HGFR), which is overexpressed in various types of cancer such as breast cancer, lung cancer, and pancreatic cancer. The drug is currently in clinical trials and has the potential to become a new treatment option for cancer patients. Over the years, Aveo Pharmaceuticals has received numerous awards and recognitions, including being recognized as one of the "50 Most Innovative Companies in the World" by Technology Review and being included in the "Forbes 200 Best Small Companies in America" ranking. In summary, Aveo Pharmaceuticals is an innovative bio-pharmaceutical company focused on the development of vital therapies for cancer patients. Aveo Pharmaceuticals' collaborative business model has enabled the company to work closely with leading academic institutions and bio-pharmaceutical companies to develop new drugs that could improve the lives of cancer patients. With Tivozanib and Ficlatuzumab, Aveo Pharmaceuticals has two promising drugs in the pipeline that have the potential to change the face of cancer treatment. Aveo Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Aveo Pharmaceuticals's Profit Margins

The profit margins of Aveo Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Aveo Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Aveo Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Aveo Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Aveo Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Aveo Pharmaceuticals stock

How much profit has Aveo Pharmaceuticals made this year?

Aveo Pharmaceuticals has made 45.86 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 140.99% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Aveo Pharmaceuticals publish its earnings?

Aveo Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Aveo Pharmaceuticals?

The profits of Aveo Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Aveo Pharmaceuticals?

You can learn more about the earnings of Aveo Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Aveo Pharmaceuticals pay?

Over the past 12 months, Aveo Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aveo Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aveo Pharmaceuticals?

The current dividend yield of Aveo Pharmaceuticals is .

When does Aveo Pharmaceuticals pay dividends?

Aveo Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aveo Pharmaceuticals?

Aveo Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aveo Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aveo Pharmaceuticals located?

Aveo Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aveo Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aveo Pharmaceuticals from 8/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/3/2024.

When did Aveo Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/3/2024.

What was the dividend of Aveo Pharmaceuticals in the year 2023?

In the year 2023, Aveo Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aveo Pharmaceuticals pay out the dividend?

The dividends of Aveo Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aveo Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aveo Pharmaceuticals

Our stock analysis for Aveo Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aveo Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.